Danaher Says Bioprocessing Shipment Delays Are Timing, Not Demand, as Masimo Integration Beats Expectations
Q2 2026 earnings call, July 21, 2026
Danaher delivered better-than-expected second-quarter revenue, earnings and cash flow, but the call was dominated by a single question analysts pressed repeatedly: why did bioprocessing consumables revenue miss, and why isn't it coming back this year. CEO Rainer Blair and CFO Matthew Gugino spent much of the session defending the underlying health of the Cytiva franchise after a handful of large commercial customers pushed out chromatography resin shipments late in the quarter.
Bioprocessing pushout: concentrated, not systemic, management insists
The headline disappointment was in Biotechnology, where core revenue grew just 2.5% and bioprocessing consumables came in below expectations. Gugino quantified the damage precisely: a roughly 500 basis point hit to bioprocessing growth in the quarter, worth $50 million to $60 million, and a bit north of $100 million shifting out of 2026 into 2027 for the full year, a headwind of a couple hundred basis points to the annual bioprocessing growth rate. Management was explicit that this was not baked back into the fourth-quarter plan. "There's some chance of this moving back into Q4. That's not within our planning assumption today," Gugino said.
Blair attributed the delays to "a few large chromatography resin shipments that were slated primarily for Q2 and Q3" moving out at customers' request "due to production schedule changes and site readiness challenges." Analysts, led by Bank of America's Michael Ryskin and Citi's Patrick Donnelly, pushed hard on whether multiple large customers delaying shipments within weeks of each other signaled something broader than isolated site issues. Blair pushed back on the framing: "I wouldn't characterize it as multiple customers. I would really characterize it as a few customers that happen to be very, very large." He pointed to mid-teens order growth in both consumables and equipment as evidence the underlying demand backdrop remains intact, and said the company's post-pandemic inventory-tracking infrastructure shows inventory levels across the market are "actually quite a bit lower than they have been in prior years," a sign this is not a repeat of the 2022-2023 destocking cycle. Management said it believes the delayed volumes "would likely then ultimately ship in 2027."
Notably, equipment revenue turned positive in the quarter after four consecutive quarters of order growth, which Blair called a twofold signal: early evidence of reshoring and brownfield capacity expansion showing up in revenue, not just orders, alongside continued underinvestment in capacity relative to demand for biologic therapeutics. He characterized the company as being "in the early innings" of a multiyear capital-expenditure cycle, though greenfield projects currently being quoted will take two to three years to convert to revenue.
Masimo off to a strong start, high single-digit growth confirmed
Danaher closed its acquisition of Masimo in early June, ahead of schedule, and gave investors their first real data point on the deal. Blair confirmed the business delivered high single-digit revenue growth in the first half of the year, calling the early results validation that "this is every fit the company that we thought it was." The unit has already secured an FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection tool, and the team has completed its first operating review, identifying opportunities for productivity gains, customer account synergies and use of the Danaher Business System's launch excellence tool. Gugino said the earlier close contributed $0.07 to $0.08 of the EPS guidance raise, on top of a $0.07 to $0.08 beat from underlying Q2 performance, with some offset from mix and foreign exchange along with a deliberate cushion built into the second-half outlook given the current environment.
Life Sciences segment posts strongest quarter in years
The more encouraging story was in Life Sciences, where core revenue grew 5.5%, ahead of internal expectations, with broad-based strength: Pall's applied filtration business grew roughly 10%, led by microelectronics demand from semiconductor and memory customers, while Beckman Life Sciences, Leica Microsystems and SCIEX all posted solid growth. Abcam delivered its best quarter since being acquired by Danaher, benefiting from improving academic conditions and traction in diversifying toward biopharma and diagnostic end markets away from its historical academic base. Blair described early "green shoots" tied to AI-enabled lab automation, particularly increased demand for autonomous lab infrastructure at Beckman. Biotech funding, he said, is finally converting from funnel activity into actual orders and, at the margin, revenue. Academic and government markets, still under 5% of Danaher's total revenue, have stabilized but management stopped short of calling an inflection, with Blair noting a durable recovery depends on more constructive government funding policy that hasn't yet materialized.
Diagnostics recovering as China headwinds fade
Diagnostics core revenue rose 2%, or 5% excluding the drag from respiratory testing, with Cepheid's nonrespiratory core revenue up low double digits on hospital-acquired infection and sexual health assay growth. Beckman Coulter's China business showed early signs of stabilization as pricing and volumes improved following the volume-based procurement disruption that began in late 2024. Leica Biosystems and Radiometer, described by Blair as "solidly into the high single digits" for the long term, are being reinforced by the pending acquisition of StatLab, a pathology consumables manufacturer generating approximately $250 million in 2025 revenue with more than 85% recurring revenue. Danaher expects StatLab to grow high single digits long-term and to be accretive to adjusted EPS in its first full year of ownership, with the deal expected to close by year-end pending regulatory approval.
Guidance raised, full-year growth still anchored at the low end
Danaher raised full-year adjusted diluted EPS guidance to $8.45 to $8.60, from a prior range of $8.35 to $8.55, implying nearly 10% EPS growth at the midpoint. Full-year core revenue growth guidance remains 3% to 4%, with management directing investors to model toward the low end given the bioprocessing pushout, even as Life Sciences performance argues for the higher end. Third-quarter revenue growth is guided to 2% to 3%, which includes an approximately 250 basis point drag from respiratory testing, implying underlying growth excluding respiratory of roughly 5%. Management continues to expect a mid-single-digit core growth exit rate in the fourth quarter as respiratory comparisons ease and China policy headwinds lessen further. Full-year free cash flow conversion stood at 124% of net income through the first half, and the company deployed roughly $900 million to repurchase 5 million shares during the quarter.